This improvement was linked to the lack of testing in the non-adenocarcinoma cohort and targeted therapies, as EGFR-mutated patients naive to tyrosine kinase inhibitors (TKIs) at BM diagnosis had a longer survival rate; the median survival rate was 14 months for EGFR/ALK-negative patients, 23 months for EGFR-mutated and 45 months for ALK-positive patients [10]. This evidence concerns the gene ALK and adenocarcinoma.